• Vaccine Name: UV-Inactivated SARS-CoV + TLR Agonist Vaccine
• Target Pathogen: SARS-CoV
• Target Disease: Severe Acute Respiratory Syndrome (SARS)
• Type: Inactivated or "killed" vaccine
• Status: Licensed
• Host Species for Licensed Use: None
• Host Species as Laboratory Animal Model: mouse
• Antigen: whole virus (Iwata-Yoshikawa et al., 2014)
• Immunization Route: subcutaneous injection
• Description: Ultraviolet radiation is used to inactivate SARS-CoV and a Toll-Like Receptor Agonist Adjuvant is added to prevent eosinophilic immunopathology (Iwata-Yoshikawa et al., 2014).

Mouse Response

• Host Strain: BALB/c
• Host age: 10 weeks (Iwata-Yoshikawa et al., 2014)
• Host gender: Female (Iwata-Yoshikawa et al., 2014)
• Vaccination Protocol: 10 μg of UV-Inactivated SARS-CoV + TLR Agonist Vaccine subcutaneously injected in back and reimmunized 6 to 7 weeks later (Iwata-Yoshikawa et al., 2014)
• Immune Response: Induced neutralizing antibodies (More than in UV-V), Lymphocyte infiltration, High levels of CXCL10 and CXCL1, Production of IFN-β, Upregulation of TNF-α1 (Iwata-Yoshikawa et al., 2014)
• Side Effects: Minor eosinophil lung infiltration (Iwata-Yoshikawa et al., 2014)
• Challenge Protocol: 10 week old BALB/c mice were vaccinated with 10 μg UV-V and boosted 6 weeks later. Four weeks afterwards, the animals were inoculated in the left nostril with 106.5 TCID50 in 30 μl of F-musX(Iwata-Yoshikawa et al., 2014)
• Efficacy: All mice survived challenge (Iwata-Yoshikawa et al., 2014).